Galectin-3 is a Nanotherapeutic Target in Graft-versus-Host Disease Mediated Kidney Injury
Magdalini Panagiotakopoulou(Memorial Sloan Kettering Cancer Center), Daniel A. Heller(Memorial Sloan Kettering Cancer Center), Thangamani Muthukumar(Cornell University), Brianna Gipson(Memorial Sloan Kettering Cancer Center), Jorge Núñez(Johns Hopkins University Applied Physics Laboratory), Emma Grabarnik(Memorial Sloan Kettering Cancer Center), Romina Ghale(Memorial Sloan Kettering Cancer Center), Anastasia I. Kousa(City Of Hope National Medical Center), Stephen Ruiz(Memorial Sloan Kettering Cancer Center), Surya V. Seshan(Cornell University), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Edgar A. Jaimes(Memorial Sloan Kettering Cancer Center), Alan M. Hanash(Memorial Sloan Kettering Cancer Center), Kaitlyn Pierpont(City Of Hope National Medical Center), Marcel R.M. van den Brink(City Of Hope National Medical Center)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
|Journal of the American Society of Nephrology|2004|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Pathologic Classification of Diabetic Nephropathy
|Journal of the American Society of Nephrology|2010|1.7k
The classification of glomerulonephritis in systemic lupus erythematosus revisited
|Kidney International|2004|1.7k